<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>888</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10430934</PubmedId>
            <Abstract>To determine whether established CD8(+) T cell memory to an epitope prominent during the replicative phase of a gamma-herpesvirus infection protects against subsequent challenge, mice were primed with a recombinant vaccinia virus expressing the p56 peptide and then boosted by intranasal exposure to an influenza A virus incorporating p56 in the neuraminidase protein. Clonally expanded populations of functional, p56-specific CD8(+) T cells were present at high frequency in both the lung and the lymphoid tissue 1 month later, immediately before respiratory challenge with gammaHV-68. This prime-and-boost regime led to a massive reduction of productive gammaHV-68 infection in the respiratory tract and, initially, to much lower levels of latency in both the regional lymph nodes and the spleen. The CD8(+) T cell response to another epitope (p79) was diminished, there was less evidence of B cell activation, and the onset of the CD4(+) T cell-dependent splenomegaly was delayed. Within 3-4 weeks of the gammaHV-68 challenge, however, the extent of latent infection in the lymph nodes and spleen was equivalent, and both groups developed the prominent infectious mononucleosis-like syndrome that is characteristic of this infection. The reverse protocol (influenza then vaccinia) seemed to be slightly less effective. Even though immune CD8(+) T cells may be present at the time and site of virus challenge, establishing a high level of CD8(+) T cell memory to lytic-phase epitopes alone does not protect against the longer-term consequences of this gammaHV infection.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>9281-6</ArticlePages>
            <ArticleTitle>A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Stevenson</LastName>
                    <ForeName>P G</ForeName>
                </Author>
                <Author>
                    <LastName>Belz</LastName>
                    <ForeName>G T</ForeName>
                </Author>
                <Author>
                    <LastName>Castrucci</LastName>
                    <ForeName>M R</ForeName>
                </Author>
                <Author>
                    <LastName>Altman</LastName>
                    <ForeName>J D</ForeName>
                </Author>
                <Author>
                    <LastName>Doherty</LastName>
                    <ForeName>P C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Immunology, St. Jude Children's Research Hospital, Memphis TN 38105, USA.</Affiliations>
            <ArticleChemicalList>Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; B-Lymphocytes(immunology); CD4-Positive T-Lymphocytes(immunology); CD8-Positive T-Lymphocytes(immunology; virology); Cells, Cultured; Female; Flow Cytometry; Gammaherpesvirinae(genetics; immunology; physiology); Herpesviridae Infections(immunology); Immunologic Memory; Interferon-gamma(biosynthesis); Lung(immunology; virology); Lymphocyte Activation; Mice; Mice, Inbred C57BL; Splenomegaly(immunology); Time Factors; Vaccinia virus(genetics; immunology); Virus Replication</ArticleMeshHeadingsList>
            <Journal>
                <Volume>96</Volume>
                <Issue>16</Issue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <Issn>0027-8424</Issn>
                <MedlineTa>Proc Natl Acad Sci U S A</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>p56</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AGPHNDMEI</LinearSequence>
                        <StartingPosition>487</StartingPosition>
                        <EndingPosition>495</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB66385.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>33708</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 9281</LocationOfData>
                <EpitopeId>1635</EpitopeId>
                <ReferenceStartingPosition>487</ReferenceStartingPosition>
                <ReferenceEndingPosition>495</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1and 2</LocationOfData>
                        <TCellId>10074</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AGPHNDMEI</LinearSequence>
                                            <StartingPosition>487</StartingPosition>
                                            <EndingPosition>495</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB66385.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>33708</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 3x10&lt;sup&gt;7&lt;/sup&gt; CFU recombinant vaccinia virus. 1 month later, mice were challenged intranasally with 600 PFU of source species.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Also 1 intranasal dose of 10^4 recombinant influenza virus assayed with similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p56</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGPHNDMEI</LinearSequence>
                                        <StartingPosition>487</StartingPosition>
                                        <EndingPosition>495</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66385.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>33708</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Priming with epitope in a recombinant vaccinia virus vector or a recombinant influenza virus vector followed by a source species challenge induces a higher number of epitope specific T cells in the lungs than in unprimed mice. No effect is seen on the number of peripheral blood epitope specific lymphocytes. Viral loads are not different in the short term (influenza vector) or in the long term (vaccinia vector).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3 and 4</LocationOfData>
                        <TCellId>10103</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AGPHNDMEI</LinearSequence>
                                            <StartingPosition>487</StartingPosition>
                                            <EndingPosition>495</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB66385.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>33708</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 3x10&lt;sup&gt;7&lt;/sup&gt; CFU recombinant vaccinia virus. 1 month later, mice were challenged intranasally with 600 PFU of source species.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Also the reverse regime, with a 1st dose of recombinant influenza and a 2nd of recombinant vaccinia, was assayed, giving a similar pattern, but with lower numbers, of peptide specific T cell activation.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p56</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGPHNDMEI</LinearSequence>
                                        <StartingPosition>487</StartingPosition>
                                        <EndingPosition>495</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66385.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>33708</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Priming with the epitope in a 2-dose schedule, 1st with recombinant vaccinia virus vector and 2nd with a recombinant influenza virus vector followed by a source species challenge induces a higher number of epitope specific T cells in the spleen in the short term and in the lungs in the short and long terms compared to unprimed mice. Lesser effects are seen in the number of peripheral blood epitope specific lymphocytes  in the short term. The total infiltrating cells in the lungs are the same in primed and unprimed mice, while splenomegaly ( mononucleosis-like disease) is delayed in primed mice, but its magnitude is similar to that in unprimed controls. Similar results are seen when the order of the immunizations is reversed.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>10126</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AGPHNDMEI</LinearSequence>
                                            <StartingPosition>487</StartingPosition>
                                            <EndingPosition>495</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB66385.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>33708</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 3x10&lt;sup&gt;7&lt;/sup&gt; CFU recombinant vaccinia virus. 1 month later, mice were challenged intranasally with 600 PFU of source species.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Also the reverse regime, with a 1st dose of recombinant influenza and a 2nd of recombinant vaccinia, was assayed, giving a similar pattern of viral load evolution in the different tissues assayed.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>33708</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Priming with the epitope in a 2-dose schedule, 1st with recombinant vaccinia virus vector and 2nd with a recombinant influenza virus vector followed by a source species challenge diminishes the viral load in the lungs in the short and long terms, and in the spleen and lymph nodes in the short term, compared to unprimed mice. Nevertheless, in the latency phase, viral load in the spleen over the long term is similar in both immunized and control groups and  induces a similar number of non-epitope specific and total T cells (mononucleosis-like disease). Similar results are seen when the order of immunization was reversed.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>p79</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NTSINFVKI</LinearSequence>
                        <StartingPosition>523</StartingPosition>
                        <EndingPosition>531</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB66451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>33708</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 9281</LocationOfData>
                <EpitopeId>46263</EpitopeId>
                <ReferenceStartingPosition>523</ReferenceStartingPosition>
                <ReferenceEndingPosition>531</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>10130</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AGPHNDMEI</LinearSequence>
                                            <StartingPosition>487</StartingPosition>
                                            <EndingPosition>495</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB66385.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>33708</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>p56</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 3x10&lt;sup&gt;7&lt;/sup&gt; CFU recombinant vaccinia virus. 1 month later, mice were challenged intranasally with 600 PFU of source species.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Also the reverse regime, with a 1st dose of recombinant influenza and a 2nd of recombinant vaccinia, was assayed, giving a similar pattern of peptide specific T cell activation.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p79</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTSINFVKI</LinearSequence>
                                        <StartingPosition>523</StartingPosition>
                                        <EndingPosition>531</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>33708</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Priming with a different, prominent lytic phase epitope (p56) in a 2-dose schedule followed by a source species challenge induces a lower number of T cells specific for this epitope in the spleen than in unprimed mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>10129</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NTSINFVKI</LinearSequence>
                                            <StartingPosition>523</StartingPosition>
                                            <EndingPosition>531</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB66451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>33708</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 3x10&lt;sup&gt;7&lt;/sup&gt; CFU recombinant vaccinia virus. 1 month later, mice were challenged intranasally with 600 PFU of source species.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p79</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTSINFVKI</LinearSequence>
                                        <StartingPosition>523</StartingPosition>
                                        <EndingPosition>531</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>33708</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Priming with the epitope in a recombinant vaccinia virus vector  followed by a source species challenge induces a higher number of epitope specific T cells in the lungs than in unprimed mice. Only a short term effect is seen in the number of peripheral blood epitope specific lymphocytes. No effect on viral load in spleen or lungs was seen.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

